About Lycia Therapeutics
Lycia Therapeutics is a company based in San Francisco (United States) founded in 2020 by Carolyn Bertozzi.. Lycia Therapeutics has raised $226.66 million across 3 funding rounds from investors including Lilly, ARE and Marshall Wace. The company has 22 employees as of December 31, 2021. Lycia Therapeutics offers products and services including LYTAC Platform and LYTAC Degraders. Lycia Therapeutics operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter San Francisco, United States
- Employees 22 as on 31 Dec, 2021
- Founders Carolyn Bertozzi
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lycia Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$226.66 M (USD)
in 3 rounds
-
Latest Funding Round
$106.6 M (USD), Series C
Apr 26, 2024
-
Investors
Lilly
& 9 more
-
Employee Count
22
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lycia Therapeutics
Lycia Therapeutics offers a comprehensive portfolio of products and services, including LYTAC Platform and LYTAC Degraders. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables development of degraders for eliminating disease-causing proteins.
Custom therapeutics to reduce levels of pathogenic proteins in diseases.
Unlock access to complete
Unlock access to complete
Funding Insights of Lycia Therapeutics
Lycia Therapeutics has successfully raised a total of $226.66M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $106.6 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $106.6M
-
First Round
First Round
(09 Jun 2020)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2024 | Amount | Series C - Lycia Therapeutics | Valuation | Venrock | |
| Sep, 2021 | Amount | Series B - Lycia Therapeutics | Valuation |
investors |
|
| Jun, 2020 | Amount | Series A - Lycia Therapeutics | Valuation | Versant Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lycia Therapeutics
Lycia Therapeutics has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, ARE and Marshall Wace. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
|
Founded Year | Domain | Location | |
|
VC & PE firm focused on healthcare sector
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lycia Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lycia Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lycia Therapeutics Comparisons
Competitors of Lycia Therapeutics
Lycia Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by the company.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lycia Therapeutics
Frequently Asked Questions about Lycia Therapeutics
When was Lycia Therapeutics founded?
Lycia Therapeutics was founded in 2020.
Where is Lycia Therapeutics located?
Lycia Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Lycia Therapeutics a funded company?
Lycia Therapeutics is a funded company, having raised a total of $226.66M across 3 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Jun 09, 2020.
How many employees does Lycia Therapeutics have?
As of Dec 31, 2021, the latest employee count at Lycia Therapeutics is 22.
What does Lycia Therapeutics do?
Lycia Therapeutics was founded in 2020 and is headquartered in San Francisco, United States. Operations focus on the biotechnology sector, where targeted protein degradation technologies are advanced to address cancer and autoimmune diseases. The company, led by founder Carolyn Bertozzi, conducts research and development activities aimed at creating novel therapeutics. Efforts are centered on preclinical and clinical-stage programs in this specialized field.
Who are the top competitors of Lycia Therapeutics?
Lycia Therapeutics's top competitors include Moderna, argenx and Forge Biologics.
What products or services does Lycia Therapeutics offer?
Lycia Therapeutics offers LYTAC Platform and LYTAC Degraders.
Who are Lycia Therapeutics's investors?
Lycia Therapeutics has 10 investors. Key investors include Lilly, ARE, Marshall Wace, Franklin Templeton, and Janus Henderson Investors.